HINT1 neuropathy in Norway: clinical, genetic and functional profiling.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
04 03 2021
Historique:
received: 18 08 2020
accepted: 16 02 2021
entrez: 5 3 2021
pubmed: 6 3 2021
medline: 22 6 2021
Statut: epublish

Résumé

Autosomal recessive axonal neuropathy with neuromyotonia has been linked to loss of functional HINT1. The disease is particularly prevalent in Central and South-East Europe, Turkey and Russia due to the high carrier frequency of the c.110G > C (p.Arg37Pro) founder variant. In a cohort of 748 Norwegian patients with suspected peripheral neuropathy, we identified two seemingly unrelated individuals, compound heterozygous for a new variant (c.284G > A, p.Arg95Gln) and the most common pathogenic founder variant (c.110G > C, p.Arg37Pro) in the HINT1 gene. Probands presented with motor greater than sensory neuropathy of various onset, accompanied by muscle stiffness and cramps in the limbs. Furthermore, they displayed non-classical symptoms, including pain in the extremities and signs of central nervous system involvement. Haplotype analysis in both patients revealed a common chromosomal background for p.Arg95Gln; moreover, the variant was identified in Swedish carriers. Functional characterization in HINT1-knockout and patient-derived cellular models, and in HNT1-knockout yeast, suggested that the new variant is deleterious for the function of HINT1 and provided mechanistic insights allowing patient stratification for future treatment strategies. Our findings broaden the genetic epidemiology of HINT1-neuropathy and have implications for molecular diagnostics of inherited peripheral neuropathies in Scandinavia.

Sections du résumé

BACKGROUND
Autosomal recessive axonal neuropathy with neuromyotonia has been linked to loss of functional HINT1. The disease is particularly prevalent in Central and South-East Europe, Turkey and Russia due to the high carrier frequency of the c.110G > C (p.Arg37Pro) founder variant.
RESULTS
In a cohort of 748 Norwegian patients with suspected peripheral neuropathy, we identified two seemingly unrelated individuals, compound heterozygous for a new variant (c.284G > A, p.Arg95Gln) and the most common pathogenic founder variant (c.110G > C, p.Arg37Pro) in the HINT1 gene. Probands presented with motor greater than sensory neuropathy of various onset, accompanied by muscle stiffness and cramps in the limbs. Furthermore, they displayed non-classical symptoms, including pain in the extremities and signs of central nervous system involvement. Haplotype analysis in both patients revealed a common chromosomal background for p.Arg95Gln; moreover, the variant was identified in Swedish carriers. Functional characterization in HINT1-knockout and patient-derived cellular models, and in HNT1-knockout yeast, suggested that the new variant is deleterious for the function of HINT1 and provided mechanistic insights allowing patient stratification for future treatment strategies.
CONCLUSION
Our findings broaden the genetic epidemiology of HINT1-neuropathy and have implications for molecular diagnostics of inherited peripheral neuropathies in Scandinavia.

Identifiants

pubmed: 33663550
doi: 10.1186/s13023-021-01746-z
pii: 10.1186/s13023-021-01746-z
pmc: PMC7934415
doi:

Substances chimiques

HINT1 protein, human 0
Nerve Tissue Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

116

Références

Nat Protoc. 2007;2(1):31-4
pubmed: 17401334
Oncotarget. 2015 Nov 3;6(34):35458-77
pubmed: 26461475
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Genet Test Mol Biomarkers. 2010 Aug;14(4):533-7
pubmed: 20642364
Mol Biol Rep. 2020 Feb;47(2):1331-1337
pubmed: 31848916
Neurogenetics. 2020 Apr;21(2):79-86
pubmed: 31832804
Neurogenetics. 2015 Jan;16(1):43-54
pubmed: 25342199
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Neuromuscul Disord. 2019 Dec;29(12):979
pubmed: 31787464
Muscle Nerve. 2015 Dec;52(6):1110-3
pubmed: 26182879
Eur J Med Genet. 2019 Mar;62(3):190-194
pubmed: 30006059
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Bioinformatics. 2016 May 15;32(10):1592-4
pubmed: 26819469
Yeast. 2011 Nov;28(11):795-8
pubmed: 21972073
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Mol Biol. 2018 Aug 17;430(17):2709-2721
pubmed: 29787766
J Biol Chem. 2002 Mar 29;277(13):10852-60
pubmed: 11805111
Nat Genet. 2012 Oct;44(10):1080-3
pubmed: 22961002
Antioxid Redox Signal. 2019 Sep 1;31(7):503-520
pubmed: 31088288
Neuromuscul Disord. 2020 Mar;30(3):265-266
pubmed: 32171572
Neuromuscul Disord. 2018 Aug;28(8):646-651
pubmed: 30001929
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Ann Phys Rehabil Med. 2012 Apr;55(3):160-73
pubmed: 22475878
Brain Behav. 2016 May 27;6(8):e00496
pubmed: 27547499
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Brain. 2017 Apr 1;140(4):868-877
pubmed: 28007994

Auteurs

Silvia Amor-Barris (S)

Molecular Neurogenomics Group, VIB-UAntwerp Center for Molecular Neurology, University of Antwerp, Unversiteitsplein 1, Building V, 2610, Antwerpen, Belgium.
Molecular Neurogenomics Group, Department of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium.

Helle Høyer (H)

Department of Medical Genetics, Telemark Hospital Trust, Sykehuset Telemark, Postboks 2900 Kjørbekk, 3710, Skien, Norway.

Lin V Brauteset (LV)

Division Elverum-Hamar, Department of Children and Youth, Innlandet Hospital Trust, Elverum, Norway.

Els De Vriendt (E)

Molecular Neurogenomics Group, VIB-UAntwerp Center for Molecular Neurology, University of Antwerp, Unversiteitsplein 1, Building V, 2610, Antwerpen, Belgium.
Molecular Neurogenomics Group, Department of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium.

Linda Strand (L)

Department of Medical Genetics, Telemark Hospital Trust, Sykehuset Telemark, Postboks 2900 Kjørbekk, 3710, Skien, Norway.

Albena Jordanova (A)

Molecular Neurogenomics Group, VIB-UAntwerp Center for Molecular Neurology, University of Antwerp, Unversiteitsplein 1, Building V, 2610, Antwerpen, Belgium.
Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria.

Geir J Braathen (GJ)

Department of Medical Genetics, Telemark Hospital Trust, Sykehuset Telemark, Postboks 2900 Kjørbekk, 3710, Skien, Norway. geibra@stfh.no.

Kristien Peeters (K)

Molecular Neurogenomics Group, VIB-UAntwerp Center for Molecular Neurology, University of Antwerp, Unversiteitsplein 1, Building V, 2610, Antwerpen, Belgium. Kristien.Peeters@uantwerpen.vib.be.
Molecular Neurogenomics Group, Department of Biomedical Sciences, University of Antwerp, Antwerpen, Belgium. Kristien.Peeters@uantwerpen.vib.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH